
Cortexyme CRTX
Quarterly report 2025-Q3
added 11-12-2025
Cortexyme Long Term Debt Current 2011-2026 | CRTX
Annual Long Term Debt Current Cortexyme
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 K | 377 K | 741 K | 238 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 741 K | 64 K | 355 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.35 | -2.91 % | $ 359 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.61 | -3.59 % | $ 189 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
437 K | $ 24.88 | -0.4 % | $ 3.04 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
1.63 M | $ 10.02 | -1.16 % | $ 133 M | ||
|
Cardiff Oncology
CRDF
|
730 K | $ 1.57 | -0.63 % | $ 105 M | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.65 | 1.3 % | $ 8.78 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
DBV Technologies S.A.
DBVT
|
1.12 M | $ 20.25 | -0.54 % | $ 2.83 B | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.55 | -4.14 % | $ 16 M | ||
|
Dyadic International
DYAI
|
34.6 K | $ 0.87 | - | $ 31.5 M | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Entera Bio Ltd.
ENTX
|
189 K | $ 1.17 | -2.1 % | $ 64 M | ||
|
Equillium
EQ
|
363 K | $ 2.0 | -0.5 % | $ 115 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Evogene Ltd.
EVGN
|
589 K | $ 0.8 | 2.49 % | $ 27.9 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Fate Therapeutics
FATE
|
4.56 M | $ 1.15 | -3.78 % | $ 137 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 26.15 | -1.1 % | $ 339 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Fennec Pharmaceuticals
FENC
|
2 K | $ 6.2 | -3.43 % | $ 177 M | ||
|
Foghorn Therapeutics
FHTX
|
923 K | $ 4.75 | -2.59 % | $ 299 M | ||
|
Amicus Therapeutics
FOLD
|
8.74 M | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 88.37 | -3.19 % | $ 27.2 B | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Fulcrum Therapeutics
FULC
|
2.4 M | $ 7.45 | -4.85 % | $ 472 K | ||
|
Galectin Therapeutics
GALT
|
22 K | $ 2.38 | -7.03 % | $ 152 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 315.4 | -4.52 % | $ 41.3 B | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Gilead Sciences
GILD
|
102 M | $ 138.37 | -1.26 % | $ 172 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Genmab A/S
GMAB
|
26 M | $ 27.13 | -2.25 % | $ 17 B | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M |